Open AccessTOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia
Author(s) -
Yanru Zhang,
Zhen Yu,
Wei Xiong,
Xuxiang Liu,
Huimin Liu,
Rui Cui,
Qi Wang,
Wen-Ming Chen,
Lugui Qiu,
Shuhua Yi
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000999
Subject(s) - chemistry , breakpoint cluster region , chronic lymphocytic leukemia , jurkat cells , b cell receptor , syk , apoptosis , signal transduction , b cell , microbiology and biotechnology , cancer research , flow cytometry , leukemia , tyrosine kinase , antibody , receptor , t cell , biology , immunology , biochemistry , immune system
TOSO, also named Fas inhibitory molecule 3 (FAIM3), has recently been identified as an immunoglobulin M (IgM) Fc receptor (FcμR). Previous studies have shown that TOSO is specifically over-expressed in chronic lymphocytic leukemia (CLL). However, the functions of TOSO in CLL remain unknown. The B-cell receptor (BCR) signaling pathway has been reported to be constitutively activated in CLL. Here, we aimed to investigate the functions of TOSO in the BCR signaling pathway and the pathogenesis of CLL.